Figure 1.
The complexity of symptoms in schizophrenia. No longer seen as a unitary illness, a variety of molecular pathways can be engaged in the disorder, and symptoms manifest
with great variability among patients. Current research into pharmacological targets seeks to address the complexity in terms
of symptom sets and receptor subtypes.